PDF file | White Paper | Promotional Content Esflorin1® Bifidobacterium longum CECT 7347 is ADM’s premier, clinically validated pro- and postbiotic for digestive health. And now, emerging research shows promise beyond digestion. Available as a live probiotic and a heat-treated postbiotic, Esflorin1® combines strain-specific science…
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement…
PDF file | White Paper | Promotional Content With 53% of global consumers saying the world is changing too fast and 60% concerned about rising costs, today’s consumers are seeking wellness solutions that provide reassurance, convenience, and meaningful health benefits. Discover the science behind…
October 13, 2026 — 2:58pm Perth-based NeuroScientific Biopharmaceuticals has cleared a key regulatory hurdle for its planned phase two trial of its innovative StemSmart cell therapy in patients with treatment-resistant Crohn’s disease, with US regulators backing the proposed study design and key elements of…
Video | Promotional Content For decades, the probiotic industry fixed its gaze on the gut. BLIS Technologies was looking somewhere else. Twenty-five years ago, BLIS identified and patented Streptococcus salivarius strains — probiotics designed specifically for the mouth and throat, at a…
PDF file | Product Brochure | Promotional Content Discover how Lactobacillus gasseri CP2305 Postbiotic can support holistic wellness through the gut-brain axis. Backed by 10 human clinical trials, this versatile ingredient offers unmatched formulation stability with opportunities for: Download the newest study snapshot to…
Gut health, IBD/IBS, reflux, liver disease, and microbiome research.
An article joins this feed when it matches these terms. Each one is also a search of its own.